Patents by Inventor James D. Moyer
James D. Moyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160096894Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.Type: ApplicationFiled: December 17, 2015Publication date: April 7, 2016Inventors: Bruce D. Cohen, Jean Beebe, JR., Penelope E. Miller, James D. Moyer, Jose Ramon Corvalan, Michael Gallo
-
Patent number: 9234041Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.Type: GrantFiled: December 19, 2013Date of Patent: January 12, 2016Assignees: Pfizer Inc., Amgen Fremont Inc.Inventors: Bruce D. Cohen, Jean Beebe, Jr., Penelope E. Miller, James D. Moyer, Jose Ramon Corvalan, Michael Gallo
-
Publication number: 20140120089Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.Type: ApplicationFiled: December 19, 2013Publication date: May 1, 2014Applicants: PFIZER INC., AMGEN FREMONT INC.Inventors: Bruce D. Cohen, Jean Beebe, Jr., Penelope E. Miller, James D. Moyer, Jose Ramon Corvalan, Michael Gallo
-
Patent number: 8642037Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.Type: GrantFiled: June 27, 2011Date of Patent: February 4, 2014Assignees: Amgen Fremont Inc., Pfizer Inc.Inventors: Bruce D. Cohen, Jean Beebe, Penelope E. Miller, James D. Moyer, Jose Ramon Corvalan, Michael Gallo
-
Publication number: 20120005767Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.Type: ApplicationFiled: June 27, 2011Publication date: January 5, 2012Applicants: PFIZER INC., AMGEN FREMONT INC.Inventors: Bruce D. Cohen, Jean Beebe, Penelope E. Miller, James D. Moyer, Jose R. Corvalan, Michael Gallo
-
Patent number: 7982024Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.Type: GrantFiled: April 8, 2010Date of Patent: July 19, 2011Assignees: Amgen Fremont Inc., Pfizer Inc.Inventors: Bruce D. Cohen, Jean Beebe, Penelope E. Miller, James D. Moyer, Jose Ramon Corvalan, Michael Gallo
-
Patent number: 7815907Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.Type: GrantFiled: June 2, 2005Date of Patent: October 19, 2010Assignees: Amgen Fremont Inc., Pfizer Inc.Inventors: Bruce D Cohen, Jean Beebe, Penelope E Miller, James D Moyer, Jose R Corvalan, Michael Gallo
-
Publication number: 20100255538Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.Type: ApplicationFiled: April 8, 2010Publication date: October 7, 2010Applicants: AMGEN FREMONT INC., PFIZER INC.Inventors: Bruce D. Cohen, Jean Beebe, Penelope E. Miller, James D. Moyer, Jose R. Corvalan, Michael Gallo
-
Patent number: 7700742Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.Type: GrantFiled: June 2, 2005Date of Patent: April 20, 2010Assignees: Amgen Fremont, Pfizer, Inc.Inventors: Bruce D Cohen, Jean Beebe, Penelope E Miller, James D Moyer, Jose R Corvalan, Michael Gallo
-
Patent number: 7087613Abstract: A method of monotherapy for a subject suffering from abnormal cell growth expressing the epidermal growth factor receptor (EGFR) which comprises orally administering to the subject a therapeutically effective amount of a crystalline polymorph of the hydrochloride salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine so as to treat the subject.Type: GrantFiled: November 18, 2004Date of Patent: August 8, 2006Assignee: OSI Pharmaceuticals, Inc.Inventors: Timothy Norris, Jeffrey W. Raggon, Richard D. Connell, James D. Moyer, Michael J. Morin, Shama M. Kajiji, Barbara A. Foster, Karen J. Ferrante, Sandra L. Silberman
-
Patent number: 7037498Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.Type: GrantFiled: January 4, 2002Date of Patent: May 2, 2006Assignees: Abgenix, Inc., Pfizer IncInventors: Bruce D. Cohen, Jean Beebe, Penelope E. Miller, James D. Moyer, Jose R. Corvalan, Michael Gallo
-
Patent number: 6900221Abstract: The present invention relates to a stable crystalline form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride designated the B polymorph, its production in essentially pure form, and its use. The invention also relates to the pharmaceutical compositions containing the stable polymorph B form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine as hydrochloride, as well other forms of the compound, and to methods of treating hyperproliferative disorders, such as cancer, by administering the compound.Type: GrantFiled: November 9, 2000Date of Patent: May 31, 2005Assignee: OSI Pharmaceuticals, Inc.Inventors: Timothy Norris, Jeffrey W. Raggon, Richard D. Connell, James D. Moyer, Michael J. Morin, Shama M. Kajiji, Barbara A. Foster, Karen J. Ferrante, Sandra L. Silberman
-
Publication number: 20040086503Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.Type: ApplicationFiled: January 4, 2002Publication date: May 6, 2004Inventors: Bruce D. Cohen, Jean Beebe, Penelope E. Miller, James D. Moyer, Jose R. Corvalan, Michael Gallo
-
Publication number: 20030171386Abstract: This invention relates to small molecules that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such small molecules in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds. The invention further relates to small molecules that are selective for erbB2 receptor over the erbB1 receptor, wherein said erbB2 inhibitor has a range of selectivities for erbB2 over erbB1 between 50-1500.Type: ApplicationFiled: December 10, 2002Publication date: September 11, 2003Applicant: Pfizer Inc.Inventors: Richard D. Connell, John C. Kath, James D. Moyer
-
Patent number: 5341601Abstract: Woven tubular gaskets for sealing the space between an oven and oven door in a self-cleaning oven. A clip for securing an oven gasket to a surface on an oven comprises a shoulder for interfacing to the surface on the oven and securing the gasket to the surface, a first retaining member integrally formed on a first side of the shoulder for efficiently retaining the clip on the gasket, and a second retaining member integrally formed on a second side of the shoulder for further fixedly retaining the clip to the gasket. Oven gaskets described and claimed herein economically and efficiently seal the space between two surfaces and reduce the number of attaching clips necessary to securedly fix the gasket to the oven by providing mounting of the clips through a braided fiberglass sleeve and a knitted wire bulb of the gasket.Type: GrantFiled: February 4, 1993Date of Patent: August 30, 1994Assignee: The Bentley-Harris Manufacturing CompanyInventor: James D. Moyer
-
Patent number: 5205075Abstract: Woven tubular gaskets for sealing the space between an oven and oven door in a self-cleaning oven. A clip for securing an oven gasket to a surface on an oven comprises a shoulder for interfacing to the surface on the oven and securing the gasket to the surface, a first retaining member integrally formed on a first side of the shoulder for efficiently retaining the clip on the gasket, and a second retaining member integrally formed on a second side of the shoulder for further fixedly retaining the clip to the gasket. Oven gaskets described and claimed herein economically and efficiently seal the space between two surfaces and reduce the number of attaching clips necessary to securedly fix the gasket to the oven by providing mounting of the clips through a braided fiberglass sleeve and a knitted wire bulb of the gasket.Type: GrantFiled: March 6, 1991Date of Patent: April 27, 1993Assignee: The Bentley-Harris Manufacturing CompanyInventor: James D. Moyer
-
Patent number: 5085204Abstract: A manner of mounting a roll-type gasket in a corner of a door, particularly a door of a self-cleaning oven. The gasket is mounted within a corner of the inner wall of the door and when the door closes, the gasket is compressed so as to roll the gasket towards a normal wall of such corner if it is restrained against movement on the associated peripheral part forming another part of such corner. The gasket is retained within the corner by utilizing pointed anchoring tabs or clips which have their points facing the normal wall so as to effect such a rolling action of the gasket when the door is closed. The gasket may be retained in place by single anchoring tabs, sets of anchoring tabs or by separately formed anchoring tabs.Type: GrantFiled: July 17, 1991Date of Patent: February 4, 1992Inventor: James D. Moyer
-
Patent number: 4946722Abstract: Tubular sleeves formed from elongated flat sheets, particularly braided sheets are disclosed. Sheet material comprised of interlaced monofilaments is cold worked by the process of drawing the interlaced monofilaments over a forming edge with sufficient force and in a direction causing permanent elongation of the molecules of material on one side of the interlaced monofilaments. The cold worked monofilaments impart a permanent bias to the sheet causing it to curl about its longitudinal axis. Sleeves so formed may be slipped over or wrapped around bundles of wires or other elongated substrates, particularly those which include terminals, plugs and connectors of irregular dimension.Type: GrantFiled: September 30, 1988Date of Patent: August 7, 1990Assignee: The Bentley-Harris Manufacturing CompanyInventor: James D. Moyer
-
Patent number: 4939819Abstract: A wraparound closure device which includes an axially compressible, radially expansible tube which is made from a fabric of engineered plastic. The tube may be braided on a circular or flat braider. If braided as a tube it is axially split to define a first and a second mating edge. Fastening means are sewn to the mating edges for selectively opening and closing the tube. The fastening means is fixed in length and thereby when it is connected to the tubular member, the tubular member is also fixed in length. However, the tubular member remains radially variable and expands and contracts to adapt to the shape of a substrate to be enclosed.Type: GrantFiled: June 28, 1989Date of Patent: July 10, 1990Assignee: The Bentley-Harris Manufacturing CompanyInventor: James D. Moyer
-
Patent number: 4865792Abstract: A device and method to prevent delamination at load-bearing apertures in structural composite substrates is disclosed. The device is a composite reinforcing grommet having a hollow, generally tubular member of braided filaments impregnated with polymer. The member may be radially deformed for insertion into an aperture in a structural composite substrate and is then capable of being radially expanded to form flanges to secure the structural composite between the flanges. A method of reinforcing a substrate having an aperture therethrough including the step of cobonding a composite reinforcing grommet to a structural composite substrate is also disclosed.Type: GrantFiled: February 2, 1988Date of Patent: September 12, 1989Inventor: James D. Moyer
-
Patent number: 5172686Abstract: A device for supplying air or medical gases in a conditioned, particularly a moistened and/or heated state to a patient, through an air pipe. The device includes at least one component to be connected to said air pipe, the component being formed by a cylinder-shaped element with an inner tube through which the moistened air flows, which cylinder-shaped element is fitted with self-regulating heating resistors which heat the air flowing through the tube, while the cylinder-shaped tube from one element at least is filled with a material which adsorbs or absorbs the water supplied by a water-supply line from a container, and has a good air-permeability.Type: GrantFiled: September 19, 1989Date of Patent: December 22, 1992Inventor: Jean-Michel Anthony